Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study

Abstract

Introduction: AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) [inv(3)/t(3;3)] was very rare. Currently, most reports of AML-inv(3)/t(3;3) were from Western countries, and few reports were from Asian countries. Racial differences in patients with AMLinv(3)/t(3;3) are still unknown. Methods:Between January 1996 and April 2018, a total of 37 AML cases with inv(3)/t(3;3) were studied retrospectively. They were collected from 2229 primary AML cases performed with conventional cytogenetic analysis (37/2229, 1.66%). Results:Here, some differences were found by comparing our data with those from Western countries. In our series, AML with inv(3)(q21q26) had a lower incidence than that with t(3;3)(q21;q26) (11 vs 26 cases). Our patients seemed to be more younger (median, 43 years) and have lower hemoglobin concentrations (median, 73 g/L) and higher platelet count (median, 351 × 10 9 /L). A higher incidence of acute monoblastic and monocytic leukemia (45.9%) was observed in our patients. Immunophenotypic studies showed that CD38 (30.8%) was not so frequently expressed as that in the earlier reports. Mutations analysis showed a high frequency of NRAS mutations (45.0%), followed by SF3B1 (15.0%), GATA2 (15.0%), FLT3-ITD (10.0%), C-Kit/D816 (5.0%), and CEBPA (5.0%), without mutation of NPM1(Exon12) or JAK2V617. Conclusion: Ethnic differences do exist between the Chinese and Western patientswith AML-inv(3)/t(3;3), and more attention should be paid involving different ethnic populations and geographic regions. K E Y W O R D S AML, Chinese, inv(3)(q21q26.2), prognosis, t(3;3)(q21;q26.2) | 381 GONG et al.

Clinical and cytopathologic characteristics of lymphoid neoplasms involved with serous effusions: a single center experience

“…SEs were performed with six-color flow cytometric analysis, using FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) [15]. A panel containing the following fluorescein isothiocyanate, or phycoerythrin-conjugated monoclonal antibodies was used for diagnosis: CD45, CD34, CD33, CD13, CD117, CD38, HLA-DR, CD11c, CD5, CD10, CD7, CD123, CD36, CD15, CD4, CD3, MPO, CD14, CD65, CD56, CD41, CD61, CD64, CD19, CD22, CD138.…”

Clinical and laboratory characteristics of lymphoid neoplasms in serous effusions: a single centre experience in China

“…Serous effusions were performed with six-color flow cytometric analysis, using FACSCalibur flow cytometer (BD Biosciences, San Jose, California). 13 A panel containing fluorescein isothiocyanate, or phycoerythrin-conjugated monoclonal antibodies against the following markers were used for diagnosis: CD45 , CD34, CD33, CD13, CD117, CD38, HLA-DR, CD11c, CD5, CD10, CD7, CD123, CD36, CD15, CD4, CD3, MPO, CD14, CD65, CD56, CD41, CD61, CD64, CD19, CD22, cKappa, cLambda, and CD138. Cases were considered positive if 20% or more of the cells expressed the specific antigen in the appropriate gate.…”